PAVMED INC (PAVM)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$4.52-4.24%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Broken: Primary pillar broken — Maintain capital discipline and manage cash burn: operating loss -70.2M vs trip -8.0M.
PAVmed is working to advance its medical device trials. It aims to control cash burn and extend its cash runway. Analysts expect revenue to grow from $340K in 2026 to $652.5K in 2027. The company is cheap but still loss-making.
PAVmed keeps losing money with no clear profit path. Cash burn is worsening, hitting -$2.6M in early 2026. Revenue and earnings remain negative and weak. The recent sharp stock selloff shows investor doubt.
The market prices in ongoing losses and weak revenue growth. Our view sees risk in cash burn and clinical progress that may delay recovery.
Breaks if: operating losses worsen beyond -$8.0M per quarter
Focus on cash management and capital structure simplification to extend runway and support operations.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is cautious, as the company is navigating through weak financial performance and high risk while trying to advance its product development.
The market seems to reflect a high valuation premium compared to peers, indicating that investors may have high expectations for future growth. However, the current financial struggles and mixed management signals suggest that these expectations may not be fully justified.
Fundamentals are likely to remain weak in the near term, given the company's loss-making status and ongoing cash burn. Management's focus on advancing product development and building commercial momentum is evident, but execution remains mixed.
The long-term thesis hinges on the performance of sector bellwethers and their impact on PAVM. Additionally, the company's ability to secure reimbursement for its products and manage cash effectively will be critical in determining its future trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat indicates improved financial performance. Narrowing losses show better capital discipline and management of cash burn. There are no new threats impacting the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 2 of last 2 quarters. Cash and cash equivalents declined from $6.5M in 2026-Q1 to $3.8M in 2026-Q2, with operating cash flow negative $2.62M and $2.66M respectively. Management emphasized capital structure simplification and cash management, but cash burn remains steady, indicating limited progress on extending runway.
“PAVmed had cash and cash equivalents of $3.8 million as of June 30, 2026.”
“PAVmed had cash and cash equivalents of $6.5 million as of March 31, 2026.”
Breaks if: clinical trial progress stalls or regresses over next year
Progress development and regulatory submission of implantable physiological monitor and medical device portfolio including PortIO and Octeris.
Stated as a priority in 2 of last 2 quarters. Management emphasized advancing clinical development of medical devices including Veris implantable physiological monitor and PortIO device. Operating expenses were $8.1M in 2026-Q1 and $7.1M in 2026-Q2, reflecting ongoing investment. The trajectory shows continued progress consistent with management's stated focus.
“Veris accelerated commercial engagement with OSU-The James and progressed implantable physiological monitor toward FDA submission.”
“Veris continued development of implantable physiological monitor with planned FDA 510(k) submission; medical device portfolio progressed under new leadership.”
Breaks if: revenue growth falls below consensus estimates next year
Progress development and regulatory submission of implantable physiological monitor and medical device portfolio including PortIO and Octeris.
Stated as a priority in 2 of last 2 quarters. Management emphasized advancing clinical development of medical devices including Veris implantable physiological monitor and PortIO device. Operating expenses were $8.1M in 2026-Q1 and $7.1M in 2026-Q2, reflecting ongoing investment. The trajectory shows continued progress consistent with management's stated focus.
“Veris accelerated commercial engagement with OSU-The James and progressed implantable physiological monitor toward FDA submission.”
“Veris continued development of implantable physiological monitor with planned FDA 510(k) submission; medical device portfolio progressed under new leadership.”
Over the next 1 to 3 years, PAVM's outlook will depend heavily on external sector conditions and internal management execution. Not investment advice.